- Home
- TOL vs ICLR Comparison
TOL vs ICLR Comparison
Compare TOL & ICLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOL
- ICLR
- Stock Information
- Founded
- TOL 1967
- ICLR 1990
- Country
- TOL United States
- ICLR Ireland
- Employees
- TOL N/A
- ICLR N/A
- Industry
- TOL Homebuilding
- ICLR Biotechnology: Commercial Physical & Biological Resarch
- Sector
- TOL Consumer Discretionary
- ICLR Health Care
- Exchange
- TOL Nasdaq
- ICLR Nasdaq
- Market Cap
- TOL 14.8B
- ICLR 17.2B
- IPO Year
- TOL N/A
- ICLR 1998
- Fundamental
- Price
- TOL $135.13
- ICLR $198.11
- Analyst Decision
- TOL Buy
- ICLR Strong Buy
- Analyst Count
- TOL 15
- ICLR 12
- Target Price
- TOL $153.67
- ICLR $284.82
- AVG Volume (30 Days)
- TOL 1.5M
- ICLR 903.2K
- Earning Date
- TOL 02-18-2025
- ICLR 02-19-2025
- Dividend Yield
- TOL 0.68%
- ICLR N/A
- EPS Growth
- TOL 21.44
- ICLR 44.49
- EPS
- TOL 15.01
- ICLR 8.99
- Revenue
- TOL $10,846,740,000.00
- ICLR $8,306,823,000.00
- Revenue This Year
- TOL $2.05
- ICLR $3.95
- Revenue Next Year
- TOL $7.21
- ICLR $2.84
- P/E Ratio
- TOL $9.00
- ICLR $22.04
- Revenue Growth
- TOL 8.52
- ICLR 3.63
- 52 Week Low
- TOL $95.46
- ICLR $183.38
- 52 Week High
- TOL $169.52
- ICLR $347.72
- Technical
- Relative Strength Index (RSI)
- TOL 53.40
- ICLR 35.86
- Support Level
- TOL $131.81
- ICLR $196.50
- Resistance Level
- TOL $137.51
- ICLR $228.29
- Average True Range (ATR)
- TOL 3.19
- ICLR 6.57
- MACD
- TOL 2.09
- ICLR -1.36
- Stochastic Oscillator
- TOL 84.08
- ICLR 5.06
About TOL Toll Brothers Inc.
Toll Brothers is the leading luxury homebuilder in the United States with an average sale price well above public competitors'. The company operates in over 60 markets across 24 states and caters to move-up, active-adult, and second-home buyers. Traditional homebuilding operations represent most of company's revenue. Toll Brothers also builds luxury for-sale and for-rent properties in urban centers across the US It has its headquarters in Horsham, Pennsylvania.
About ICLR ICON plc
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.